Conceptus (CPTS) Stock Price, News & Analysis

Conceptus, Inc. designs, develops, markets and promotes solutions in women’s healthcare. The Company’s flagship product is the Essure permanent birth control procedure, which is the non-surgical permanent birth control system. The Essure delivers a soft and flexible insert into a woman’s fallopian tubes, causing a benign tissue in-growth, which blocks the fallopian tubes. Successfully placed Essure inserts and the subsequent tissue growth around, and through the inserts prohibits the egg from traveling through the fallopian tube, preventing conception. In October 2011, the Company acquired from its Dutch distributor certain assets and all distribution rights of the Essure device. In October 2011, it purchased certain assets of Sigma Medical and established a wholly owned subsidiary in the Netherlands, Conceptus B.V. (BV). During the year ended December 31, 2011, approximately 600,000 women worldwide have undergone the Essure procedure.